Patients on weight-loss drugs seek skin tightening and fat reduction; aesthetic practices pivot to address post-GLP-1 body changes.
Body contouring treatments are gaining traction among GLP-1 drug users who experience rapid weight loss but face stubborn fat deposits and skin laxity. Practices report increased demand for RF microneedling, radiofrequency skin tightening, cryolipolysis, and ultrasound-assisted liposuction as patients seek to address the aesthetic aftermath of semaglutide and tirzepatide use.
This is not a marginal trend. GLP-1 adoption has accelerated dramatically, and the aesthetic sequelae—loose skin, uneven fat loss, cellulite—create a new patient cohort with specific, high-intent needs. Practices that bundle body contouring with injectables and facial treatments are capturing larger wallet share per patient.
GLP-1 patients seeking body contouring represent a high-intent, high-LTV cohort for diversified practices.
The economics favor practices with diverse modalities. A patient on GLP-1 who books Morpheus8 for body tightening is also a candidate for cellulite RF, cryolipolysis, or even surgical liposuction referral. Practices without body contouring capability are leaving revenue on the table. Device manufacturers are responding: expect more body-specific protocols and marketing from InMode, Cutera, and BTL.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
